Watchmaker Genomics expanded manufacturing capacity by securing a long-term lease for about 100,000 square feet at Flatiron Park in Boulder, Colorado. The facility is designed to more than double capacity and support growth across R&D, quality, logistics, and operations, with the site expected to be operational in the second half of 2027 after qualification. Watchmaker manufactures specialized enzymes, reagents, and kits used in DNA and RNA analysis for next-generation sequencing and molecular diagnostics. The move signals rising demand for scale-ready reagents and ISO 13485-governed quality systems in applied genomics.